Compare AbbVie Inc (ABBV) vs Walmart Stores Inc (WMT) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Walmart (WMT) stock trades at $113.26, up 1.26% today, with a neutral technical signal and strong analyst consensus. The company demonstrates robust fundamentals with revenue growth to $681.0B in 2025 and net income of $19.4B, alongside consistent earnings beats. Recent news highlights operational innovations like drone delivery expansion and AI tools, while maintaining a solid dividend.

Outlook remains positive with a $142 consensus price target, though risks include competitive pressures and margin sustainability. The stock presents a long-term opportunity given its defensive positioning and growth initiatives, but investors should monitor execution against Amazon and consumer spending trends.